Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
l-pipecolic acid as-APF is a synthetic derivative of antiproliferative factor (APF), which itself is a frizzled protein 8-related sialoglycopeptide known to inhibit epithelial cell proliferation, particularly in bladder carcinoma and other tumor types. The l-pipecolic acid *as*-APF variant incorporates l-pipecolic acid into the peptide backbone of the APF derivative. It demonstrates potent, dose-dependent inhibition of proliferation across a wide range of carcinoma and melanoma cell lines, apparently independent of cell type or mutation status (p53, ras). Mechanistically, APF and its analogs, including l-pipecolic acid *as*-APF, act by binding to cytoskeletal associated protein 4 at the cell membrane, resulting in inhibition of cell proliferation, suppression of HB-EGF and matrix metalloproteinase 2 (MMP2) production, and attenuation of in vitro cell invasion[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on l-pipecolic acid as-APF.